Browsing Tag
Medicus Pharma Ltd.
3 posts
Can DNA predict who responds to Teverelix? A new UAE endometriosis trial aims to find out
UAE clears Medicus Pharma’s Teverelix Phase 2a trial, pairing controlled estradiol suppression with genomic profiling in endometriosis.
SkinJect trial clearance gives Medicus Pharma a regulatory win as Nasdaq pressure builds
Medicus Pharma gains FDA clearance for its SkinJect Gorlin syndrome trial as stricter endpoints, secured debt and Nasdaq risks shape the outlook.
Why clinicians are watching SkinJect as a potential alternative to repeated Mohs surgery
Find out how SkinJect could challenge repeated Mohs surgery and reshape basal cell carcinoma care. Read the full analysis now.